WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
12,56 US$
arrow_upward
+0,48%(+0,060) 1K
16-okt, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoWXXWY tikeri uchun statistika yaratilmoqda...
Ochish
12,29 US$
Yuqori
12,56 US$
Past
12,20 US$
Bozor kapitali
198,43 mlrd
Oʻrtacha hajm
61,89 ming
Hajmi
110,85 ming
52 haftalik eng yuqori
14,80 US$
52 haftalik eng past
7,30 US$
Beta
0,01
Muomaladagi aksiyalar
2,06 mlrd
Xodimlar soni
15 ming
Ochish
12,29 US$
Yuqori
12,56 US$
Past
12,20 US$
Bozor kapitali
198,43 mlrd
Oʻrtacha hajm
61,89 ming
Hajmi
110,85 ming
52 haftalik eng yuqori
14,80 US$
52 haftalik eng past
7,30 US$
Beta
0,01
Muomaladagi aksiyalar
2,06 mlrd
Xodimlar soni
15 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Simply Wall Street
·
32 daqiqa oldin
What Viasat Doubters Got Wrong
Mitrade
·
15 daqiqa oldin
Weekly Market Wrap: AI debt fears hit the Nasdaq as Brent pushes back above $100
Bloomberg.com
·
5 soat oldin
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Wuxi Biologics Cayman ADR haqida
CEOZhisheng Chen
Xodimlar soni14,7 ming
Asos solingan2010
Bosh ofislar-
Sektor-
Veb-saytwuxibiologics.com